In the News

Jul 25, 2023

Drug Discovery World

Immunotherapy is Here to Stay

Jul 05, 2023

OncLive

Dr Ibrahim on the Study of Eftilagimod Alpha Plus Paclitaxel in HER2-Negative or -Low Breast Cancer

Jun 29, 2023

Financial Review

Ramsay boasts M&A appeal despite failed KKR bid

Jun 28, 2023

Endpoints News

Immutep picks up more funds for LAG-3 oncology and autoimmune studies

Jun 17, 2023

OncLive

First-line Eftilagimod Alpha Plus Pembrolizumab Generates OS Benefit in PD-L1+ NSCLC

Media

Immutep: fighting the good fight, 17 December 2020 – CEO Marc Voigt speaks with Share Cafe’s Tim McGowen about the company’s operations, clinical trials and future developments